ReviewFrontiers in oral health2026
The correlation between periodontitis and fatty liver and the improvement of NAFLD by periodontal treatment.
Review in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence highlights a pathophysiological interplay between periodontitis and non-alcoholic fatty liver disease yet the mechanistic underpinnings and therapeutic implications remain contentious. This review systematically elucidates molecular crosstalk through the "oral-gut-liver axis" and "oral-liver axis". Methods: A comprehensive literature review was conducted using PubMed, Scopus and Web of Science, employing keywords related to periodontal disease and non-alcoholic fatty liver disease. Results: Analysis of 16 original studies revealed that periodontitis and its associated pathogens promote the progression of non-alcoholic fatty liver disease through multiple pathways: (1) activation of hepatic inflammatory responses (elevated IL-6, IL-17, and TNF-α levels), (2) exacerbation of metabolic dysregulation (increased HOMA-IR, ALT, and AST), and (3) disruption of the oral-gut-liver axis. Notably, non-surgical periodontal therapy demonstrated therapeutic potential by simultaneously improving periodontal health and attenuating non-alcoholic fatty liver disease progression through reduction of hepatic pro-inflammatory cytokines and fibrogenic mediators. Conclusions: Periodontitis may exacerbate systemic inflammation via the oral-liver and oral-gut-liver axes, inducing insulin resistance and promoting non-alcoholic fatty liver disease. Non-surgical periodontal therapy can improve non-alcoholic fatty liver disease, but methodological heterogeneity in current studies necessitates further prospective research to clarify their relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.